Pipeline breakthroughs & novel mechanisms
Key Questions
What is diranersen and its status in Alzheimer's trials?
Biogen's diranersen is an antisense oligonucleotide targeting tau that has advanced to late-stage trials. It aims to address both intracellular and extracellular tau pathology.
How effective is lecanemab in slowing Alzheimer's progression?
Lecanemab has demonstrated 27% slowing of cognitive decline in trials. It helps roughly half of patients maintain cognitive function longer in mild stages.
What progress has been made with zervimesine for DLB?
Cognition Therapeutics has completed FDA meetings for zervimesine in dementia with Lewy bodies. Phase 2 studies support its potential for psychosis and related symptoms.
How is focused ultrasound being used in Alzheimer's treatment?
Noninvasive focused ultrasound trials show promise in opening the blood-brain barrier to improve drug delivery or clear pathology. Results from recent clinical studies support further development.
What is the potential of semaglutide in Alzheimer's?
Semaglutide is under investigation in the Evoke trials for neuroprotective effects in Alzheimer's. Updates indicate ongoing evaluation for cognitive benefits beyond diabetes treatment.
Are there new drugs targeting mechanisms beyond amyloid?
Bristol Myers is exploring agitation targets and other pathways beyond amyloid. Low-dose lithium and synaptic regeneration approaches also represent novel mechanisms in early trials.
What is Leucettinib-21 and its target population?
Leucettinib-21 is a DYRK1A kinase inhibitor entering Phase 1 trials for Down syndrome-related Alzheimer's. It aims to address cognitive challenges in this group.
How are care models adapting to new anti-amyloid therapies?
Institutions like UAB are redesigning Alzheimer's care pathways to incorporate anti-amyloid treatments. This includes better monitoring and multidisciplinary support for approved drugs.
Biogen diranersen tau; Annovis buntanetap; zervimesine Ph3/FDA progress; lecanemab 27% slowing; focused ultrasound; semaglutide. New: anti-amyloid care redesign; Bristol Myers agitation targets; Cognition zervimesine DLB talks; low-dose lithium MCI; IDOL enzyme; synaptic regeneration frontier; Leucettinib-21 DYRK1A inhibitor Phase 1 (Down syndrome).